Immune checkpoint inhibitor treatment and atherosclerotic cardiovascular disease: an emerging clinical problem
Antibody-mediated blockade of co-inhibitory molecules such as cytotoxic T lymphocyte-associated protein 4, PD1 and PDL1 elicits potent antitumor responses and improves the prognosis of many patients with cancer. As these immune checkpoint inhibitors (ICIs) are increasingly prescribed to a diverse pa...
Saved in:
| Main Authors: | Esther Lutgens, Marie José Kersten, Tom T.P. Seijkens, Kikkie Poels, Suzanne I.M. Neppelenbroek, M. Louisa Antoni |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-06-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/9/6/e002916.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cancer patients receiving immune checkpoint inhibitor therapy are at an increased risk for atherosclerotic cardiovascular disease
by: Esther Lutgens, et al.
Published: (2020-05-01) -
Adverse cardiovascular events and cardiac imaging findings in patients on immune checkpoint inhibitors
by: Jennifer M. Kwan, et al.
Published: (2024-01-01) -
Adverse cardiovascular events and cardiac imaging findings in patients on immune checkpoint inhibitors.
by: Jennifer M Kwan, et al.
Published: (2024-01-01) -
Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes
by: Anupam Kotwal, et al.
Published: (2019-05-01) -
Emerging immune checkpoint inhibitors for the treatment of oropharyngeal squamous cell carcinoma
by: Pandiselvi Ravi, et al.
Published: (2024-12-01)